SOURCE: AtheroGenics

October 23, 2007 09:40 ET

AtheroGenics to Report Third Quarter 2007 Financial Results on October 25, 2007

ATLANTA, GA--(Marketwire - October 23, 2007) - AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced that it will release its third quarter 2007 financial results on Thursday, October 25, 2007, before the U.S. financial markets open.

Conference Call and Webcast Information

Company officials will discuss third quarter results via conference call and webcast on Thursday, October 25, 2007, at 9:00 a.m. EDT. Participants may access the live conference call by dialing 877-407-8031 (domestic) or 201-689-8031 (international). To access the webcast, please visit the AtheroGenics Investor Relations website at www.atherogenics.com. A replay of the conference call can be accessed approximately one hour after the conclusion of the call by dialing 877-660-6853 (domestic) or 201-612-7415 (international), account number 286, conference ID number 259742. A replay of the webcast will be archived on the Company's website until January 26, 2008.

About AtheroGenics

AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including diabetes and coronary heart disease (atherosclerosis). AtheroGenics is commencing the ANDES Phase III clinical trial to study its lead anti-inflammatory drug candidate, AGI-1067, in patients with diabetes. In addition, the Company has a clinical-stage development program studying AGI-1096, an oral agent in Phase I that is being developed for the prevention of organ transplant rejection in collaboration with Astellas. For more information about AtheroGenics, please visit http://www.atherogenics.com.

Contact Information

  • CONTACT:
    Corporate Communications
    AtheroGenics, Inc.
    Donna L. Glasky
    (678) 336-2517
    Email Contact

    Media:
    Schwartz Communications, Inc.
    Jayme Maniatis
    (781) 684-0770
    Email Contact

    Investors:
    Stern Investor Relations, Inc.
    Lilian Stern
    (212) 362-1200
    Email Contact